Is There a Role for Allogeneic Transplantation in Chronic Myeloid Leukemia?

Authors and Disclosures

Noam Benyamini¹ and Jacob M Rowe*<sup>1–3

1</sup>Department of Hematology & Bone Marrow Transplantation, Rambam Health Care Campus, Haifa 31096, Israel
²Department of Hematology, Shaare Zedek Medical Center, Jerusalem 91031, Israel
³Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel

Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.

*Author for correspondence
rowe@jimmy.harvard.edu

Sidebar

Key Issues

• The majority of CML patients can be successfully managed with tyrosine kinase inhibitors (TKIs), and will not need allogeneic hemopoietic cell transplantation.

• Allogeneic transplantation remains the only curative modality and even the only treatment option in selected patients.

• Patients in chronic phase failing at least two TKIs or those intolerant to all TKIs available, including patients with T351I mutation not responding to ponatinib, should be evaluated for allogeneic hemopoietic cell transplantation.

• Patients in blast crisis and selected patients in accelerated phase should be referred to transplantation.

• The very young patients should be also considered for allogeneic transplantation.